Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yohimbine is a naturally occurring indole alkaloid derived from the bark of the African tree Pausinystalia johimbe and also found in Rauwolfia serpentina. It acts primarily as a selective antagonist of pre-synaptic alpha-2-adrenergic receptors, leading to increased release of norepinephrine and enhanced cholinergic activity. This mechanism underlies its use in treating erectile dysfunction (impotence), particularly of vascular, diabetic, or psychogenic origin. Yohimbine has also been used as a mydriatic (to dilate pupils), for weight loss (due to its lipolytic effects), and for conditions such as xerostomia (dry mouth) and orthostatic hypotension, though evidence for these uses is limited or inconclusive. At higher concentrations, yohimbine interacts with other receptors including alpha-1 adrenergic, several serotonin receptor subtypes (notably 5-HT1A as partial agonist; 5-HT1B/1D/2A/2B as antagonist), and dopamine D2/D3 receptors. Yohimbine is available by prescription in some countries but is also present in dietary supplements; however, supplement content can be highly variable[3][4][5][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yohimbine.